OxyContin Abuse-Deterrent Formulation Has Addicts Switching To Heroin
New England Journal of Medicine report notes an increase in heroin use among patients with opioid dependence following the introduction of reformulated OxyContin; Purdue post-marketing study also finds an increase in heroin-related calls to poison control centers.
You may also be interested in...
Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee recommends against approval of Zogenix’s Zohydro ER as it seeks safer formulations and stricter REMS for all extended-release/long-acting opioids.
Endo citizen petition asks FDA to determine that the company’s old formulation was withdrawn for safety reasons and to decline approval of ANDAs of that formulation; Purdue Pharma files third OxyContin citizen petition.